Lianke Liu

机构：Jiangsu Province Hospital, Nanjing Medical University · ORCID：0000-0002-0978-2729

发表论文 43 篇 · 总被引 964 次 · h-index 12

代表论文

• Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial (2022 · BMJ · 被引 509)
• MiR‐326/Sp1/KLF3: A novel regulatory axis in lung cancer progression (2018 · Cell Proliferation · 被引 66)
• Microarray expression profiling and bioinformatics analysis of circular RNA expression in lung squamous cell carcinoma. (2018 · PubMed · 被引 28)
• Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial (2021 · 癌症：英文版 · 被引 26)
• Targeted DNA profiling and the prevalence of NTRK aberrations in Chinese patients with head and neck cancer (2021 · Oral Oncology · 被引 14)
• Real world experience with camrelizumab in patients with advanced non-small cell lung cancer: a prospective multicenter cohort study (NOAH-LC-101) (2023 · Translational Lung Cancer Research · 被引 12)